What is Cerebrolysin?

Cerebrolysin (FPF-1070) is a peptide preparation made from purified porcine brain tissue, consisting of a mixture of low-molecular-weight neuropeptides and free amino acids. It is studied for proposed neurotrophic and neuroprotective effects.

What does research suggest about Cerebrolysin?

Preclinical animal studies report neurotrophic effects, and it has been investigated clinically for conditions such as stroke and dementia in countries where it is prescribed. Independent human evidence is mixed, and reviews have reached inconsistent conclusions about its clinical benefit.

Is Cerebrolysin approved by the FDA?

No. Cerebrolysin is not approved in the United States. It is registered and used as a prescription medicine in some other countries, but its regulatory status varies by region.

Is Cerebrolysin safe?

Where it is prescribed, Cerebrolysin is administered and monitored by clinicians. Material obtained outside regulated channels is unverified for identity and purity, and Cerebrolysin should not be considered a validated therapy outside its approved uses.

What are the side effects of Cerebrolysin?

Injection-site reactions have been reported. As with any parenteral preparation, adverse effects are possible, which is one reason it is used under prescription and clinical monitoring where it is marketed.

What is Cerebrolysin used for?

In countries where it is registered, Cerebrolysin has been used clinically for neurological conditions including stroke recovery, dementia, and traumatic brain injury. It is not an approved treatment for these or any indication in the United States.

Why is Cerebrolysin controversial despite being used as a medicine for decades?

It is genuinely marketed as a prescription drug in a number of countries, which can give an impression of strong validation. The controversy is that long, widespread regional use has not been matched by convincing independent evidence — several systematic reviews of stroke and dementia trials have found the data limited or mixed. Regulatory acceptance in one country is not the same as proven efficacy, and it has never been approved in the US.

How does Cerebrolysin differ from single-sequence research peptides like Semax or Selank?

Cerebrolysin is not one defined peptide with a known sequence. It is a biologically derived mixture — an enzymatic hydrolysate of porcine brain tissue — containing many low-molecular-weight peptides and free amino acids. That makes its exact composition harder to characterize and standardize than a chemically synthesized single-sequence peptide, and it is one reason batch-to-batch consistency and mechanism are frequently discussed.

Is material sold on the research-chemical market the same as the pharmaceutical product?

Not necessarily. Where Cerebrolysin is a licensed medicine it is manufactured, prescribed, and monitored under regulatory oversight. Material offered through the unregulated research market carries no such guarantees of identity, composition, or purity, and because the product is a complex biological mixture rather than a simple molecule, its contents cannot be assumed to match the pharmaceutical preparation.

Where can I buy Cerebrolysin and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Cognitive / Neuro

Buy Cerebrolysin – Vendors, Prices, Testing and Evidence

Buy Cerebrolysin

Also known as: FPF-1070

Evidence grade C — Early / Preclinical

Short answer

A porcine-brain-derived peptide preparation used clinically in some countries for neurological conditions.

Where can you buy Cerebrolysin?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids of neuronal origin.

What is not established?

Regional clinical use; independent evidence is mixed.

Safety

Where used it is prescribed and monitored; research-market material is unverified.

Regulatory status

Used as a medicine in some countries; not approved in the US. Prescription where marketed.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Vendor comparison

Buy Cerebrolysin: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	Cerebrolysin research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

Cerebrolysin research product

Code PEPTIDES10 −10% · discount code details

What is it?

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids of neuronal origin.

Research and evidence

Cerebrolysin, also identified by the research code FPF-1070, is a peptide preparation derived from purified porcine (pig) brain tissue. Rather than being a single molecule, it is a standardized mixture of low-molecular-weight neuropeptides and free amino acids of neuronal origin. It falls within the cognitive and neurological category of compounds and is administered parenterally where it is marketed. In several countries it is registered and used as a prescription medicine for neurological indications, while in others—including the United States—it is not an approved drug. This split status is central to understanding Cerebrolysin: it is simultaneously a clinically used medicine in some regions and an unapproved substance in others.

Cerebrolysin is researched primarily for its proposed neurotrophic and neuroprotective properties. The scientific interest stems from laboratory and animal findings suggesting its peptide fraction may mimic the action of naturally occurring nerve growth factors, potentially supporting neuronal survival and signaling. Because of this, it has been investigated in the context of stroke recovery, dementia, and traumatic brain injury in the regions where it is prescribed. Animal (preclinical) studies have reported neurotrophic effects, which form much of the mechanistic rationale behind its continued study.

The honest evidence picture is mixed. Cerebrolysin has an extensive history of regional clinical use and a sizable body of trials, but independent reviews and meta-analyses have reached inconsistent conclusions about its clinical benefit, and methodological concerns have been raised about parts of the literature. It carries an evidence rating of "C" on this reference, reflecting real human use alongside genuine uncertainty about effect size. Material sold outside of regulated prescription channels is unverified for identity and purity, and no claim here should be read as establishing Cerebrolysin as a proven treatment. This page is an educational reference and does not provide medical advice, dosing, or protocols.

Evidence grade: C

Regional clinical use; independent evidence is mixed. Neurotrophic effects reported.

Human evidence

Regional clinical use; independent evidence is mixed.

Animal and preclinical evidence

Neurotrophic effects reported.

Proposed mechanisms

Discussed neurotrophic and neuroprotective effects

Safety concerns and known side effects

Where used it is prescribed and monitored; research-market material is unverified.

Injection-site reactions reported

Regulatory status

Used as a medicine in some countries; not approved in the US. Prescription where marketed.

Cerebrolysin research timeline

Mid-20th century
An Austrian pharmaceutical company develops Cerebrolysin (also coded FPF-1070) as an enzymatically processed hydrolysate of porcine brain tissue, yielding a mixture of low-molecular-weight peptides and amino acids.
1970s–1980s
Clinical use spreads across parts of Europe and later post-Soviet states and Asia, marketed as a prescription treatment for dementia, stroke, and traumatic brain injury.
1990s–2000s
Controlled human trials are run in conditions such as vascular dementia, Alzheimer's-type dementia, and acute ischemic stroke, with reported neurotrophic and neuroprotective rationale.
2010s
Independent systematic reviews (including Cochrane analyses of stroke and vascular dementia) conclude the evidence is limited, mixed, or insufficient to establish a clear clinical benefit.
Ongoing to early 2020s
Cerebrolysin remains a prescription medicine marketed in a number of countries while never being approved by the US FDA; independent evidence stays contested.

Frequently asked questions about Cerebrolysin

What is Cerebrolysin?: Cerebrolysin (FPF-1070) is a peptide preparation made from purified porcine brain tissue, consisting of a mixture of low-molecular-weight neuropeptides and free amino acids. It is studied for proposed neurotrophic and neuroprotective effects.
What does research suggest about Cerebrolysin?: Preclinical animal studies report neurotrophic effects, and it has been investigated clinically for conditions such as stroke and dementia in countries where it is prescribed. Independent human evidence is mixed, and reviews have reached inconsistent conclusions about its clinical benefit.
Is Cerebrolysin approved by the FDA?: No. Cerebrolysin is not approved in the United States. It is registered and used as a prescription medicine in some other countries, but its regulatory status varies by region.
Is Cerebrolysin safe?: Where it is prescribed, Cerebrolysin is administered and monitored by clinicians. Material obtained outside regulated channels is unverified for identity and purity, and Cerebrolysin should not be considered a validated therapy outside its approved uses.
What are the side effects of Cerebrolysin?: Injection-site reactions have been reported. As with any parenteral preparation, adverse effects are possible, which is one reason it is used under prescription and clinical monitoring where it is marketed.
What is Cerebrolysin used for?: In countries where it is registered, Cerebrolysin has been used clinically for neurological conditions including stroke recovery, dementia, and traumatic brain injury. It is not an approved treatment for these or any indication in the United States.
Why is Cerebrolysin controversial despite being used as a medicine for decades?: It is genuinely marketed as a prescription drug in a number of countries, which can give an impression of strong validation. The controversy is that long, widespread regional use has not been matched by convincing independent evidence — several systematic reviews of stroke and dementia trials have found the data limited or mixed. Regulatory acceptance in one country is not the same as proven efficacy, and it has never been approved in the US.
How does Cerebrolysin differ from single-sequence research peptides like Semax or Selank?: Cerebrolysin is not one defined peptide with a known sequence. It is a biologically derived mixture — an enzymatic hydrolysate of porcine brain tissue — containing many low-molecular-weight peptides and free amino acids. That makes its exact composition harder to characterize and standardize than a chemically synthesized single-sequence peptide, and it is one reason batch-to-batch consistency and mechanism are frequently discussed.
Is material sold on the research-chemical market the same as the pharmaceutical product?: Not necessarily. Where Cerebrolysin is a licensed medicine it is manufactured, prescribed, and monitored under regulatory oversight. Material offered through the unregulated research market carries no such guarantees of identity, composition, or purity, and because the product is a complex biological mixture rather than a simple molecule, its contents cannot be assumed to match the pharmaceutical preparation.
Where can I buy Cerebrolysin and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

CognitionNeuroprotection

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10